CO2022000660A2 - Composiciones de proteína anti-vegf y métodos para producir la misma - Google Patents

Composiciones de proteína anti-vegf y métodos para producir la misma

Info

Publication number
CO2022000660A2
CO2022000660A2 CONC2022/0000660A CO2022000660A CO2022000660A2 CO 2022000660 A2 CO2022000660 A2 CO 2022000660A2 CO 2022000660 A CO2022000660 A CO 2022000660A CO 2022000660 A2 CO2022000660 A2 CO 2022000660A2
Authority
CO
Colombia
Prior art keywords
producing
methods
same
protein compositions
vegf protein
Prior art date
Application number
CONC2022/0000660A
Other languages
English (en)
Inventor
Shawn Lawrence
Amy Johnson
Meghan Casey
Jaimie Mastrogiacomo
Shunhai Wang
Ning Li
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=76210828&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO2022000660(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of CO2022000660A2 publication Critical patent/CO2022000660A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0031—Serum-free culture media
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21004—Trypsin (3.4.21.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/80—Fraction collectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Vascular Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden proteínas anti-VEGF y métodos para producir tales composiciones.
CONC2022/0000660A 2019-12-06 2022-01-25 Composiciones de proteína anti-vegf y métodos para producir la misma CO2022000660A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962944635P 2019-12-06 2019-12-06
US202063065012P 2020-08-13 2020-08-13
PCT/US2020/046823 WO2021112924A1 (en) 2019-12-06 2020-08-18 Anti-vegf protein compositions and methods for producing the same

Publications (1)

Publication Number Publication Date
CO2022000660A2 true CO2022000660A2 (es) 2022-01-28

Family

ID=76210828

Family Applications (6)

Application Number Title Priority Date Filing Date
CONC2021/0018192A CO2021018192A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018181A CO2021018181A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018214A CO2021018214A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018234A CO2021018234A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018203A CO2021018203A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2022/0000660A CO2022000660A2 (es) 2019-12-06 2022-01-25 Composiciones de proteína anti-vegf y métodos para producir la misma

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CONC2021/0018192A CO2021018192A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018181A CO2021018181A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018214A CO2021018214A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018234A CO2021018234A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma
CONC2021/0018203A CO2021018203A2 (es) 2019-12-06 2021-12-30 Composiciones de proteína anti-vegf y métodos para producir la misma

Country Status (18)

Country Link
US (31) US11053280B2 (es)
EP (6) EP3906249A1 (es)
JP (11) JP2022547652A (es)
KR (12) KR20220035393A (es)
CN (6) CN114206907A (es)
AU (12) AU2020397865C1 (es)
BR (6) BR112021025438A2 (es)
CA (4) CA3129193C (es)
CO (6) CO2021018192A2 (es)
IL (16) IL309560A (es)
MX (9) MX2022006760A (es)
MY (12) MY190623A (es)
NZ (6) NZ781142A (es)
PE (6) PE20221788A1 (es)
SG (6) SG11202110972UA (es)
TW (6) TW202128743A (es)
WO (7) WO2021112923A1 (es)
ZA (3) ZA202107646B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021025438A2 (pt) * 2019-12-06 2022-06-21 Regeneron Pharma Composições de proteínas anti-vegf e métodos para produzir as mesmas
WO2022234412A1 (en) 2021-05-03 2022-11-10 Lupin Limited A process for purification of fc-fusion proteins
AR127006A1 (es) * 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
WO2023137143A1 (en) * 2022-01-14 2023-07-20 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2023230486A2 (en) * 2022-05-23 2023-11-30 Inhalon Biopharma, Inc. Compositions and methods for inhalable therapeutics

Family Cites Families (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1522343A (en) 1923-05-02 1925-01-06 Thom Clarence Magnetic separator
US4534972A (en) 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
EP0283942B1 (en) 1987-03-24 1992-05-20 W.R. Grace & Co.-Conn. Basal nutrient medium for cell culture
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US20030108545A1 (en) 1994-02-10 2003-06-12 Patricia Rockwell Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US5705364A (en) 1995-06-06 1998-01-06 Genentech, Inc. Mammalian cell culture process
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
JP2000517188A (ja) 1996-08-30 2000-12-26 ライフ テクノロジーズ，インコーポレイテッド 無血清哺乳動物細胞培養培地およびその使用
US5804420A (en) 1997-04-18 1998-09-08 Bayer Corporation Preparation of recombinant Factor VIII in a protein free medium
US6475725B1 (en) 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
SE519827C2 (sv) 1998-03-30 2003-04-15 Viranative Ab Näringsmedium innehållande metionin samt användning av detta
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US7303746B2 (en) 1999-06-08 2007-12-04 Regeneron Pharmaceuticals, Inc. Methods of treating eye disorders with modified chimeric polypeptides
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
EP1544299B1 (en) * 1999-06-08 2008-12-17 Regeneron Pharmaceuticals, Inc. VEGF receptor chimeras for the treatment of eye disorders characterized by vascular permeability
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
AU2669501A (en) * 1999-11-30 2001-06-12 Smithkline Beecham Plc New use
SK288131B6 (sk) 2000-05-26 2013-10-02 Bristol-Myers Squibb Company CTLA4 mutant molecule or nucleic acid molecule, vector and host vector system, host cell, CTLA4 mutant protein, method for producing and use thereof, pharmaceutical composition and regulation method
US6900056B2 (en) 2001-02-15 2005-05-31 Centocor, Inc. Chemically defined medium for cultured mammalian cells
CA2443493A1 (en) 2001-04-13 2002-10-24 Wyeth Surface proteins of streptococcus pyogenes
US20030087372A1 (en) 2001-06-13 2003-05-08 Genentech, Inc. Methods of culturing animal cells and polypeptide production in animal cells
GB0130228D0 (en) 2001-12-18 2002-02-06 Hansa Medica Ab Protein
US8777906B1 (en) 2002-01-24 2014-07-15 Robin Scott Gray Syringe with inspection window
BR0316882A (pt) 2002-12-23 2005-10-25 Bristol Myers Squibb Co Melhora na qualidade de produtos em processos de cultura de células de mamìferos para a produção de proteìnas
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
CN100537751C (zh) 2004-05-12 2009-09-09 华东理工大学 一种适合中国仓鼠卵巢细胞培养的无血清培养基
US7335491B2 (en) 2004-08-27 2008-02-26 Wyeth Research Ireland Limited Production of anti-abeta
EP1812557A4 (en) * 2004-10-29 2009-11-04 Centocor Ortho Biotech Inc COMPOSITIONS OF CHEMICALLY DEFINED MEDIA
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
ZA200708845B (en) 2005-03-25 2010-07-28 Regeneron Pharma Vegf antogonist formulations
EP1901773B1 (en) * 2005-06-09 2012-03-07 Hansa Medical AB Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
CN1778903A (zh) 2005-09-29 2006-05-31 华东理工大学 一种动物细胞高密度连续灌注培养方法
PT1974014T (pt) 2006-01-04 2017-05-26 Baxalta Inc Meios de cultura celulares livres de oligopeptídeos
CN100502945C (zh) 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
JP5216002B2 (ja) 2006-06-16 2013-06-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 硝子体内投与に適したｖｅｇｆアンタゴニスト製剤
CA2657248C (en) 2006-07-13 2018-10-30 Wyeth Production of glycoproteins
ZA200900836B (en) * 2006-08-28 2010-05-26 Ares Trading Sa Process for the purification of FC-fusion proteins
DK2073842T4 (da) 2006-09-10 2024-01-15 Glycotope Gmbh Anvendelse af humane celler af myloid leukæmioprindelse til udtrykkelse af anti-stoffer
US10259860B2 (en) 2007-02-27 2019-04-16 Aprogen Inc. Fusion proteins binding to VEGF and angiopoietin
PT2137655E (pt) 2007-04-16 2012-09-14 Momenta Pharmaceuticals Inc Produtos de glicoproteína definidos e métodos relacionados
WO2008154014A2 (en) 2007-06-11 2008-12-18 Amgen Inc. A method for culturing mammalian cells to improve recombinant protein production
WO2009027041A1 (en) 2007-08-31 2009-03-05 F. Hoffmann-La Roche Ag Glycosylation profile analysis
CA2709029A1 (en) * 2007-12-21 2009-07-02 Bianca Eser Stability testing of antibodies
EP2308907B1 (en) 2008-07-31 2014-01-01 Kyoto University Molding material containing unsaturated polyester resin and microfibrillated plant fiber
KR20110060911A (ko) 2008-09-26 2011-06-08 쉐링 코포레이션 고 역가 항체 생산
CA2761817A1 (en) 2009-05-26 2010-12-02 Momenta Pharmaceuticals, Inc. Production of glycoproteins
CN103833855A (zh) 2009-06-26 2014-06-04 瑞泽恩制药公司 容易地分离的具有天然免疫球蛋白形式的双特异性抗体
KR101756354B1 (ko) 2009-07-31 2017-07-26 백스터 인터내셔널 인코포레이티드 Ａｄａｍｔｓ 단백질 발현을 위한 세포 배양 배지
EP2491055A2 (en) * 2009-10-20 2012-08-29 Abbott Laboratories Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography
EP2325296A1 (en) 2009-11-20 2011-05-25 LEK Pharmaceuticals d.d. Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) content
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
SG10201802789VA (en) 2011-01-13 2018-05-30 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
CN102653729B (zh) 2011-03-04 2014-07-16 上海赛金生物医药有限公司 一种用于中国仓鼠卵巢细胞的培养基
EP2697361A1 (en) 2011-04-11 2014-02-19 Cellcura Asa Protein-free culture media products for manufacturing viral-based vaccines
DK2702164T3 (en) 2011-04-29 2016-02-01 Biocon Res Ltd METHOD FOR REDUCING heterogeneity OF ANTIBODIES AND METHOD OF PRODUCING THESE ANTIBODIES
WO2012147048A2 (en) 2011-04-29 2012-11-01 Biocon Research Limited Methods for reducing accumulation of lactate during culturing and method for producing polypeptide
RU2018119112A (ru) 2011-05-27 2018-11-07 Эббви Байотекнолоджи Лтд. Композиции и способы на основе dac hyp
WO2013028330A2 (en) 2011-08-19 2013-02-28 Emd Millipore Corporation Methods of reducing level of one of more impurities in a sample during protein purification
WO2013054250A1 (en) * 2011-10-10 2013-04-18 Dr Reddy's Laboratories Limited Purification method
CA2951856A1 (en) * 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
US20130281355A1 (en) * 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
CN102757496B (zh) * 2012-06-07 2014-06-18 山东泉港药业有限公司 一种抗vegf抗体片段的纯化制备方法
DE202012011016U1 (de) * 2012-07-03 2012-11-28 Novartis Ag Aflibercept-Spritze
US9695416B2 (en) * 2012-07-18 2017-07-04 Siemens Healthcare Diagnostics Inc. Method of normalizing biological samples
MX2015001550A (es) * 2012-08-02 2015-05-11 Sanofi Sa Articulo de fabricacion que comprende aflibercept o ziv-aflibercept.
WO2014035475A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
EP2722673B1 (en) * 2012-10-17 2017-07-12 Hexal AG Improved method of mapping glycans of glycoproteins
US9217168B2 (en) 2013-03-14 2015-12-22 Momenta Pharmaceuticals, Inc. Methods of cell culture
CN103146648A (zh) 2013-03-14 2013-06-12 北京京蒙高科干细胞技术有限公司 一种无动物源的淋巴细胞无血清培养基
US8956830B2 (en) 2013-03-14 2015-02-17 Momenta Pharmaceuticals, Inc. Methods of cell culture
US20140271622A1 (en) 2013-03-14 2014-09-18 Momenta Pharmaceuticals, Inc. Methods of cell culture
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
DK2968495T3 (da) * 2013-03-15 2019-10-14 Daniel J Capon Hybrid immunoglobulin indeholdende en ikke-peptid-bro
EP3712252A1 (en) 2013-03-15 2020-09-23 F. Hoffmann-La Roche AG Cell culture compositions with antioxidants and methods for polypeptide production
CN103773732B (zh) 2013-06-08 2016-05-11 李锋 一种化学成分确定的培养基、其应用及大规模培养哺乳动物细胞的生产工艺
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
WO2015058369A1 (en) * 2013-10-23 2015-04-30 Sanofi (China) Investment Co., Ltd. Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
JP6609561B2 (ja) 2014-02-04 2019-11-20 バイオジェン・エムエイ・インコーポレイテッド 翻訳後修飾を濃縮するための、フロースルーモードにおける陽イオン交換クロマトグラフィーの使用
CN104073464A (zh) 2014-07-08 2014-10-01 西藏天虹科技股份有限责任公司 一种cho细胞无血清培养基及其制备方法
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
US10683340B2 (en) * 2015-03-12 2020-06-16 Medimmune, Llc Method of purifying albumin-fusion proteins
KR101867134B1 (ko) 2015-03-23 2018-06-12 한양대학교 산학협력단 포유류 세포를 이용하여 목적 물질을 고효율로 생산하기 위한 세포 배양 배지, 이를 이용한 세포 배양 방법 및 목적 물질의 생산 방법
CA2996643A1 (en) 2015-04-01 2016-10-06 Boehringer Ingelheim International Gmbh Cell culture medium
CN105002242A (zh) 2015-07-23 2015-10-28 苏州康聚生物科技有限公司 用于cho细胞中高效表达重组人促甲状腺激素的无血清培养基及其应用
TW202330904A (zh) * 2015-08-04 2023-08-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
CN107922975B (zh) 2015-08-12 2022-06-28 诺华股份有限公司 治疗眼科病症的方法
WO2017069158A1 (ja) * 2015-10-22 2017-04-27 プロテノバ株式会社 イムノグロブリン結合ポリペプチド
MX2018006171A (es) 2015-11-18 2018-12-19 Formycon Ag Jeringa de plastico precargada que contiene un antagonista de vegf.
RU2734958C2 (ru) * 2015-11-18 2020-10-26 Формикон Аг Предварительно заполненная фармацевтическая упаковка, содержащая жидкий состав на основе антагониста vegf
CN105368808B (zh) * 2015-11-30 2019-04-30 苏州康聚生物科技有限公司 一种IdeS蛋白酶、其制备方法及应用
CA3009161A1 (en) 2015-12-22 2017-06-29 Regeneron Pharmaceuticals, Inc. Combination of anti-pd-1 antibodies and bispecific anti-cd20/anti-cd3 antibodies to treat cancer
CN108602889A (zh) 2015-12-22 2018-09-28 瑞泽恩制药公司 医治急性成淋巴细胞性白血病的双特异性抗cd20/抗cd3抗体
EP3196646B1 (en) * 2016-01-19 2019-12-18 Hexal AG Methods of mapping protein variants
CA3011638C (en) 2016-01-26 2023-01-10 Formycon Ag Liquid formulation of a vegf antagonist
WO2017168296A1 (en) 2016-03-29 2017-10-05 Navya Biologicals Pvt. Ltd A process for purification of fc-fusion proteins
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
CN106279412A (zh) * 2016-09-12 2017-01-04 广东东阳光药业有限公司 一种抗vegf类单克隆抗体的纯化方法
CA3037732A1 (en) 2016-09-23 2018-03-29 Regeneron Pharmaceuticals, Inc. Anti-steap2 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind steap2 and cd3, and uses thereof
MD3515487T2 (ro) 2016-09-23 2023-11-30 Regeneron Pharma Anticorpi bispecifici anti-MUC16-CD3 și conjugate anticorp anti-MUC16-medicament
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US11135266B2 (en) 2016-11-21 2021-10-05 Just-Evotec Biologics, Inc. Aflibercept formulations and uses thereof
WO2018116198A1 (en) 2016-12-23 2018-06-28 Serum Institute Of India Private Limited Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies
US10941178B2 (en) * 2017-03-17 2021-03-09 Gilead Sciences, Inc. Method of purifying an antibody
KR101861163B1 (ko) 2017-04-26 2018-05-25 삼천당제약주식회사 안과용 약학 조성물
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN111344410B (zh) * 2017-08-17 2023-09-15 济世易为生物有限公司 从宿主细胞半乳糖凝集素和其他污染物中纯化糖基化蛋白的方法
CA3079565A1 (en) * 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
EP3713591A1 (en) * 2017-11-20 2020-09-30 Just-Evotec Biologics, Inc. Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
CN109929027B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 采用线性洗脱步骤的重组融合蛋白纯化方法
CN109929038B (zh) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Vegf捕获剂融合蛋白的纯化方法
WO2019173767A1 (en) * 2018-03-08 2019-09-12 Coherus Biosciences Inc. Stable aqueous formulations of aflibercept
US11426446B2 (en) 2018-03-08 2022-08-30 Coherus Biosciences, Inc. Stable aqueous formulations of aflibercept
WO2019178151A1 (en) * 2018-03-13 2019-09-19 Amgen Inc. Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis
WO2019217927A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
WO2020102740A2 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
AU2020216368A1 (en) 2019-01-30 2021-08-12 Amgen Inc. Aflibercept attributes and methods of characterizing and modifying thereof
EP3969564A1 (en) 2019-05-16 2022-03-23 Formycon AG Method for reducing methionine oxidation in recombinant proteins
KR102286892B1 (ko) * 2019-07-08 2021-08-06 삼천당제약주식회사 안과용 단백질 제제의 정제방법
BR112021025438A2 (pt) * 2019-12-06 2022-06-21 Regeneron Pharma Composições de proteínas anti-vegf e métodos para produzir as mesmas

Also Published As

Publication number Publication date
KR20240007293A (ko) 2024-01-16
JP2024026116A (ja) 2024-02-28
US20220033472A1 (en) 2022-02-03
ZA202107646B (en) 2022-03-30
AU2020398125B2 (en) 2022-12-15
US11174283B2 (en) 2021-11-16
IL288351B2 (en) 2024-05-01
WO2021112924A1 (en) 2021-06-10
US20220235116A1 (en) 2022-07-28
PE20221788A1 (es) 2022-11-25
CN114401994A (zh) 2022-04-26
AU2020397803C1 (en) 2023-05-11
NZ781136A (en) 2023-05-26
MY193355A (en) 2022-10-06
US11505593B2 (en) 2022-11-22
AU2020397865C1 (en) 2023-04-27
AU2023201586A1 (en) 2023-04-13
US20210284684A1 (en) 2021-09-16
AU2023201585A1 (en) 2023-04-13
US20220396608A1 (en) 2022-12-15
CN114206925A (zh) 2022-03-18
IL296893B1 (en) 2024-01-01
AU2020398547A1 (en) 2021-10-28
US20220048975A1 (en) 2022-02-17
KR102519236B1 (ko) 2023-04-10
SG11202110968VA (en) 2021-10-28
US20220009998A1 (en) 2022-01-13
MY190686A (en) 2022-05-10
US20210371501A1 (en) 2021-12-02
IL296863B1 (en) 2023-06-01
US20230119662A1 (en) 2023-04-20
NZ781138A (en) 2023-05-26
US20220389081A1 (en) 2022-12-08
SG11202110953UA (en) 2021-10-28
AU2020396490A1 (en) 2021-10-28
BR112021025769A2 (pt) 2022-04-12
US20210214733A1 (en) 2021-07-15
AU2023201748A1 (en) 2023-06-01
WO2021112927A1 (en) 2021-06-10
US20210206833A1 (en) 2021-07-08
PE20221770A1 (es) 2022-11-11
CO2021018203A2 (es) 2022-01-17
JP2022547652A (ja) 2022-11-15
MX2021014863A (es) 2022-09-28
JP2023171771A (ja) 2023-12-05
US20230041349A1 (en) 2023-02-09
IL288355B (en) 2022-11-01
SG11202110972UA (en) 2021-10-28
US11104715B2 (en) 2021-08-31
US11407813B2 (en) 2022-08-09
US11186625B2 (en) 2021-11-30
JP2022552052A (ja) 2022-12-15
US11299532B2 (en) 2022-04-12
IL302921A (en) 2023-07-01
MX2022012042A (es) 2022-10-27
IL296863B2 (en) 2023-10-01
US11542317B1 (en) 2023-01-03
PE20221790A1 (es) 2022-11-25
US11505594B2 (en) 2022-11-22
US20220009997A1 (en) 2022-01-13
MX2021014862A (es) 2022-09-27
US20220275054A1 (en) 2022-09-01
IL288367A (en) 2022-01-01
TW202128744A (zh) 2021-08-01
US11548932B2 (en) 2023-01-10
US11459374B2 (en) 2022-10-04
US20220098280A1 (en) 2022-03-31
US11098311B2 (en) 2021-08-24
AU2020398125C1 (en) 2023-05-11
IL288360A (en) 2022-01-01
CO2021018192A2 (es) 2022-01-17
US11472861B2 (en) 2022-10-18
AU2020398830A1 (en) 2021-10-28
CO2021018181A2 (es) 2022-01-17
IL288360B1 (en) 2023-05-01
KR20240005206A (ko) 2024-01-11
BR112021025438A2 (pt) 2022-06-21
IL288357B (en) 2022-11-01
US20230357357A1 (en) 2023-11-09
IL288352A (en) 2022-01-01
MY190626A (en) 2022-04-27
MY190627A (en) 2022-04-27
US11649273B2 (en) 2023-05-16
MX2022006758A (es) 2023-01-30
BR112021025359A2 (pt) 2022-06-21
KR20230051296A (ko) 2023-04-17
US20220162289A1 (en) 2022-05-26
KR20220038349A (ko) 2022-03-28
IL304390A (en) 2023-09-01
IL288351A (en) 2022-01-01
IL288355B2 (en) 2023-03-01
IL296864A (en) 2022-11-01
IL296893A (en) 2022-12-01
TW202128991A (zh) 2021-08-01
CA3172631A1 (en) 2021-06-10
IL288351B1 (en) 2024-01-01
EP3931303A1 (en) 2022-01-05
IL288357B2 (en) 2023-03-01
US11535663B2 (en) 2022-12-27
US20210214430A1 (en) 2021-07-15
AU2020398547B2 (en) 2022-12-22
CN114206914A (zh) 2022-03-18
US11459373B2 (en) 2022-10-04
KR20230051297A (ko) 2023-04-17
IL288352B (en) 2022-11-01
TW202134256A (zh) 2021-09-16
NZ781143A (en) 2023-05-26
EP3906302A1 (en) 2021-11-10
IL288357A (en) 2022-01-01
KR20220038348A (ko) 2022-03-28
WO2021112925A1 (en) 2021-06-10
IL296864B1 (en) 2023-06-01
ZA202107647B (en) 2022-03-30
IL309560A (en) 2024-02-01
JP2022550930A (ja) 2022-12-06
IL288360B2 (en) 2023-09-01
EP3906250A1 (en) 2021-11-10
US20220033471A1 (en) 2022-02-03
AU2020397865A1 (en) 2021-10-28
EP3931204A1 (en) 2022-01-05
BR112022001016A2 (pt) 2022-08-16
AU2020397803A1 (en) 2021-10-28
IL309491A (en) 2024-02-01
MX2022006759A (es) 2023-01-30
KR20230152810A (ko) 2023-11-03
NZ781137A (en) 2023-05-26
CA3159586A1 (en) 2021-06-10
US11753459B2 (en) 2023-09-12
MY190624A (en) 2022-04-27
MY193351A (en) 2022-10-06
IL296893B2 (en) 2024-05-01
IL296863A (en) 2022-11-01
ZA202107644B (en) 2022-03-30
IL301888A (en) 2023-06-01
BR112021025158A2 (pt) 2022-06-21
US11180540B2 (en) 2021-11-23
JP2022548197A (ja) 2022-11-17
US11485770B2 (en) 2022-11-01
MX2022006788A (es) 2022-07-11
US20220227835A1 (en) 2022-07-21
JP2022548818A (ja) 2022-11-22
US20210171605A1 (en) 2021-06-10
MY193353A (en) 2022-10-06
CN114423783A (zh) 2022-04-29
US20220127331A1 (en) 2022-04-28
CA3129193C (en) 2022-10-04
TW202128743A (zh) 2021-08-01
US20230272044A1 (en) 2023-08-31
CN114206924A (zh) 2022-03-18
MX2022006760A (es) 2023-01-30
EP3906303A1 (en) 2021-11-10
US11440950B2 (en) 2022-09-13
US20220009999A1 (en) 2022-01-13
IL302538A (en) 2023-07-01
AU2023201588A1 (en) 2023-04-13
US20210206832A1 (en) 2021-07-08
JP2022547651A (ja) 2022-11-15
US20230331812A1 (en) 2023-10-19
MY193350A (en) 2022-10-06
MX2023005421A (es) 2023-05-23
US20230068199A1 (en) 2023-03-02
AU2020396490B2 (en) 2022-12-15
AU2023201589A1 (en) 2023-04-06
JP2024009950A (ja) 2024-01-23
AU2020396490C1 (en) 2023-04-27
JP2024009949A (ja) 2024-01-23
US11286290B2 (en) 2022-03-29
KR102519234B1 (ko) 2023-04-10
CA3129193A1 (en) 2021-06-10
WO2021112928A1 (en) 2021-06-10
US20220227836A1 (en) 2022-07-21
KR20220038062A (ko) 2022-03-25
AU2020397803B2 (en) 2022-12-15
IL288367B (en) 2022-10-01
KR20240005222A (ko) 2024-01-11
IL288352B2 (en) 2023-03-01
US11958894B2 (en) 2024-04-16
US20210171570A1 (en) 2021-06-10
MX2022011973A (es) 2022-11-09
SG11202110955VA (en) 2021-10-28
US20230235019A1 (en) 2023-07-27
AU2020398830B2 (en) 2022-12-15
WO2021112929A1 (en) 2021-06-10
JP2023179531A (ja) 2023-12-19
WO2021112923A1 (en) 2021-06-10
IL288355A (en) 2022-01-01
US11306135B2 (en) 2022-04-19
CA3172625A1 (en) 2021-06-10
US11732025B2 (en) 2023-08-22
CO2021018214A2 (es) 2022-01-17
KR20220041083A (ko) 2022-03-31
US11098112B2 (en) 2021-08-24
MY190623A (en) 2022-04-27
PE20221791A1 (es) 2022-11-25
AU2020397865B2 (en) 2022-12-15
CN114206907A (zh) 2022-03-18
WO2021112926A1 (en) 2021-06-10
TW202122417A (zh) 2021-06-16
AU2023201590A1 (en) 2023-04-13
BR112021025432A2 (pt) 2022-06-21
MY193354A (en) 2022-10-06
US20240067701A1 (en) 2024-02-29
AU2020398830C1 (en) 2023-04-27
IL296512A (en) 2022-11-01
TW202128745A (zh) 2021-08-01
IL296512B2 (en) 2023-12-01
US11053280B2 (en) 2021-07-06
AU2020398125A1 (en) 2021-10-28
IL288367B2 (en) 2023-02-01
SG11202110964QA (en) 2021-10-28
EP3906249A1 (en) 2021-11-10
KR20220038347A (ko) 2022-03-28
MY193349A (en) 2022-10-06
AU2020398547C1 (en) 2023-05-11
PE20221789A1 (es) 2022-11-25
KR20220035393A (ko) 2022-03-22
PE20221261A1 (es) 2022-08-16
NZ781142A (en) 2023-05-26
CO2021018234A2 (es) 2022-01-17
SG11202110958QA (en) 2021-10-28
IL296864B2 (en) 2023-10-01
MY190625A (en) 2022-04-27
NZ781145A (en) 2023-05-26
IL296512B1 (en) 2023-08-01
CA3172631C (en) 2024-01-02
KR102619866B1 (ko) 2024-01-04

Similar Documents

Publication Publication Date Title
CO2022000660A2 (es) Composiciones de proteína anti-vegf y métodos para producir la misma
EA202090090A1 (ru) Включение неприродных нуклеотидов и способы с ними
BR112018074453A2 (pt) proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
EA202190808A2 (ru) Составы антител к cd38 для подкожного введения и их применение
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
CR20180154A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
UY36889A (es) Moléculas de unión a linfopoyetina estromal timica (tslp) y métodos de uso de las moléculas
BR112021024236A2 (pt) Proteínas multiespecíficas
BR112022008092A2 (pt) Métodos de preparação de uma amostra enriquecida para sequenciamento polipeptídico
EA201890177A1 (ru) Мультиспецифические связывающие белки
WO2020128870A3 (en) Methods of producing heterodimeric antibodies
CO2023015915A2 (es) Anticuerpos anti-ccr8
EA202191403A1 (ru) Композиция с высокой концентрацией белка
BR112018005464A2 (pt) expressão de proteínas contendo fc
AR119791A1 (es) Composiciones de proteína anti-vegf y métodos para producirlas
CO2022003053A2 (es) Proteínas de unión a antígenos
BR112018071142A2 (pt) métodos de fabricação de formulações nutricionais
EA201992800A1 (ru) Замещенные хинолинилциклогексилпропанамидные соединения и улучшенные способы их получения
PL427190A1 (pl) Fosfoorganiczne pochodne peptydowe będące analogami N-końcowej sekwencji białka Smac, sposób ich wytwarzania oraz ich zastosowanie